Antibody Synthesis In Vitro


Antibodies are specific proteins that recognise nearly any chemical structure. During in vivo immunisation B cells are activated by antigen. Antigen‐specific cells proliferate and some differentiate into antibody‐secreting plasma cells. Monoclonal antibody technology was first reported by Köhler and Milstein in 1975. Briefly, B cells with specificity for a known antigen were fused with myeloma to make them immortal. Hybridomas grow in culture indefinitely and secrete monoclonal antibodies (mAbs) of a desired specificity. Hybridoma technology and antibody engineering have contributed in Biomedicine to the diagnosis of malignancies, tissue typing, identification of individual cell types, detection of cytokines, growth factors and hormones. The mAbs have become important in human immunotherapy and diagnosis. Murine mAbs have limited potential in human therapeutic applications due to human immune response to the murine antibodies. Several strategies for human mAbs production for immunotherapy are described in this article. Monoclonal antibodies have also a wide range of applications in Health and Food Sciences, Environmental Sciences, Technology and Experimental Sciences among others.

Key Concepts

  • Antigen is a molecule that binds specifically to B cell receptor (BCR) or soluble antibodies. T cell receptor (TCR) recognise processed antigen presented by MHC (major histocompatibility complex).
  • Epitope or antigenic determinant is part of an antigen that is recognised specifically by TCR‐MHC or by BCR or by soluble antibodies.
  • Immunogen is an antigen that generates a cellular and humoral immune response.
  • Antibody is an immunoglobulin that recognises specifically a particular antigenic epitope.
  • Antibody affinity is the strength of binding between a single binding site of an antibody and a single antigenic determinant or epitope.
  • Plasma B cells are differentiated B cells that, after binding to an antigen, secrete soluble antibodies.
  • Hybridoma is a hybrid cell line obtained by cell fusion of an immortalised lymphocyte tumor line, or myeloma, and B lymphocytes with defined antigen specificities.
  • Monoclonal antibody is an immunoglobulin with specificity for one antigenic determinant or epitope, derived from a single B‐clone.
  • Antibody immunotherapy is applied in immunopathology and in cancer. The main therapeutic agents are human or humanised monoclonal antibodies.

Keywords: specific antibodies; monoclonal antibody technology; hybridomas; B cell diversity; B cell immortalisation

Figure 1. Generation of monoclonal antibody secretory hybridomas by B cell fusion. (a) , high‐affinity B cells are developed in germinal centres and plasma B cells secrete high‐affinity antibodies.
Figure 2. Several strategies for human monoclonal antibody production. (a) human–mouse heterohybridoma, (b) antibody‐transfected cell line, (c) virus immortalised B cells, (d) human–human hybridoma, (e) transgenic mouse hybridoma.


Alkan SS (2004) Monoclonal antibodies: the story of a discovery that revolutionized science and medicine. Nature Reviews 4 (2): 153–156.

Azzazy HME and Highsmith WE Jr (2002) Phage display technology: clinical applications and recent innovations. Clinical Biochemistry 35: 425–445.

Cerrutti A , Puga I and Cols M (2012) New helping friends for B cells. European Journal of Immunology 42: 1956–1968.

Chin J , Sohn Y , Lee SH , Park YI and Choi MJ (2003) Production of neutralizing human monoclonal antibody directed to tetanus toxin in CHO cells. Biologicals 31: 45–53.

Cinamon G , Zachariah MA , Lam OM , Foss FW and Cyster JG (2008) Follicular shuttling of marginal zone B cells facilitates antigen transport. Nature Immunology 9 (1): 54–62.

den Haan JM , Mebius RE and Kraal G (2012) Stromal cells of the mouse spleen. Frontiers in Immunology 3: 1–5.

Foltz IN , Karow M and Wasserman SM (2013) Evolution and emergence of therapeutic monoclonal antibodies. What cardiologists need to know. Circulation 127: 2222–2230.

Jerne NK and Nordin AA (1963) Plaque formation in agar by single antibody‐producing cells. Science 140: 405–406.

Jones PT , Dear PH , Foote J , Neuberger MS and Winter G (1986) Replacing the complementarity‐determining regions in a human antibody with those from a mouse. Nature 321 (6069): 522–525.

Karpas A , Dremucheva A and Czepulkowski BH (2001) A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proceedings of the National Academy of Sciences of the USA 98 (4): 1799–1804.

Kraal G and Mebius RE (2006) New insights into the cell biology of the marginal zone of the spleen. International Review of Cytology 250: 175–215.

Kellermayer Z , Fisi V , Mijalj M , et al. (2014) Marginal zone macropahage receptor MARCO is trapped in conduits formed by follicular dendritic cells in the spleen. Journal of Histochemistry & Cytochemintry 62 (6): 436–449.

Köhler G and Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (5517): 495–497.

Kontermann R (2012) Dual targeting strategies with bispecific antibodies. MAbs 4 (2): 182–197.

Lanzavecchia A , Corti D and Sallusto F (2007) Human monoclonal antibodies by immortalization of memory B cells. Current Opinion in Biotechnology 18: 523–528.

Li F , Vijayasankaran N , Shen A , Kiss R and Amanullah A (2010) Cell culture processes for monoclonal antibody production. MAbs 2 (5): 466–477.

Lonberg N (2005) Human antibodies from transgenic animals. Nature Biotechnology 23 (9): 1117–1125.

Pasqualini R and Arap W (2004) Hybridoma‐free generation of monoclonal antibodies. Proceedings of the National Academy of Sciences of the USA 101: 257–259.

Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228 (4705): 1315–1317.

Velikovsky CA , Cassataro J , Sanchez M , et al. (2000) Single‐shot plasmid DNA intrasplenic immunization for the production of monoclonal antibodies. Persistent expression of DNA. Journal of Immunological Methods 224: 1–7.

Zola H , Mohandas AP and Krumbiegel D (2013a) Monoclonal antibodies: diagnostic uses. In: eLS, –Chichester. John Wiley and Sons, Ltd. DOI: 10.1002/9780470015902.a0002177.pub3.

Zola H , Thomas D and Lopez A (2013b) Monoclonal antibodies: therapeutic uses. In: eLS. Chichester: John Wiley and Sons, Ltd. DOI: 10.1002/9780470015902.a0002176.pub3.

Further Reading

Delves PJ , Martin SJ , Burton DR and Roitt IM (2011) Roitt's Essential Immunology, 12th edn. Oxford: Wiley Blackwell Science.

Owen JA , Punt J and Strandford SA (2013) Kuby Immunology, 7th edn. New York: W. H. Freeman and Company.

Paul WE (2012) Fundamental Immunology, 7th edn. Philadelphia, PA: Lippincott, Williams & Wilkins.

Special issue (2000) 25 years of monoclonal antibodies. Immunology Today 21 (8): 355–412.

Zola H (2000) Monoclonal Antibodies. Oxford, UK: BIOS Scientific Publishers Ltd.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Iborra, Antoni, Martínez, Paz, and Palacio, José Ramón(Jul 2015) Antibody Synthesis In Vitro . In: eLS. John Wiley & Sons Ltd, Chichester. [doi: 10.1002/9780470015902.a0001115.pub2]